Paluch-ShimonS, PaganiO, PartridgeAH, et al.ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast. 2017; 35:203–217.
2.
PogodaK, NiwińskaA, Jagiełło-GruszfeldA, et al.Clin Oncol Pract. 2015; 11(5):276–91.
3.
JachR, PabianW, SpaczyńskiR, et al.Recommendations of the fertility preservation working group in oncological, hematological and other patients treated with gonadotoxic therapies “ONCOFERTILITY” (GROF) of the polish society of oncological gynecology. J Adolesc Young Adult Oncol. 2017; 6(3):388–95.
4.
LambertiniM, CeppiM, PoggioF, et al.Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015; 26:2408–419.
5.
MooreHC, UngerJM, PhilipsKA, et al.Goserelin for oovarian protection during breast-cancer adjuvant chemotherapy. N Eng J Med. 2015; 10:923–32.
